NCT01018979已完成2 期
A Phase II, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 6
- 主要终点
- Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD).
研究概览
简要总结
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female 18 to 70 years of age inclusive
- •Patients with confirmed pathology diagnosis of MM, NHL or HD
- •Potential candidate for autologous stem cell transplantation at Investigator's discretion
- •≦ 2 prior regimens of cytotoxic chemotherapy (rituximab, thalidomide, and bortezomib will not be considered as cytotoxic chemotherapy)
- •> 4 weeks since last cycle of chemotherapy prior to the study drug administration
- •Total dose of melphalan received ≦ 200 mg in the most recent chemotherapy treatment
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Recovered from all acute toxic effects of prior chemotherapy at Investigator's discretion
- •White blood cell (WBC) count ≧ 3.0 x 109/L on screening laboratory assessments
- •Absolute neutrophil count ≧ 1.5 x 109/L on screening laboratory assessments
- •Platelet count ≧ 100 x 109/L on screening laboratory assessments
- •Serum creatinine ≦ 2.2 mg/dL on screening laboratory assessments
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin < 2 x upper limit of normal (ULN) on screening laboratory assessments
- •Negative for human immunodeficiency virus (HIV)
- •Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's discretion
- •For females, one of the following criteria must be fulfilled:
- •At least one year post-menopausal, or
- •Surgically sterile, or
- •Willing to use a double-barrier method [intrauterine device (IUD) plus condom, spermicidal gel plus condom] of contraception throughout the study
- •Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from study Day 1 until 28 days after the last dose of TG-0054
- •Able to provide the signed informed consent
排除标准
- •Received radiation therapy around the pelvic or spinal area within 6 months prior to the study drug administration
- •>10% bone marrow involvement of lymphoma in NHL patients
- •Failed previous stem cell collection [failed to collect 2 x 106 CD34+ cells/kg within 4 apheresis sessions after receiving granulocyte colony-stimulating factor (G-CSF)]
- •Patients who have undergone previous stem cell transplantation procedure
- •Received G-CSF within 2 weeks prior to the study drug administration
- •History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or squamous cell carcinoma of the skin
- •History of other hematologic disorders including bleeding or thromboembolic disease
- •History of poor and uncontrollable cardiovascular or pulmonary disease such as myocardial infarction, cardiac arrhythmias, transient ischemic attack, stroke or Chronic Obstructive Pulmonary Disease (COPD) patients hospitalized more than two times a year due to underlying disease
- •Diagnosis of sickle cell anemia or documented sickle cell trait
- •Uncontrollable malignancy with MM, NHL or HD, or carcinomatous meningitis, at Investigator's discretion
- •Any infection required antibiotic treatment or unexplained fever above 38 °C within 3 days prior to dosing
- •Pregnant or breast-feeding
- •Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study
- •Received any other investigational drug within 1 month before entering the study
研究组 & 干预措施
TG-0054 (2.24 mg/kg)
Experimental
TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
干预措施: TG-0054 (2.24 mg/kg) (Drug)
TG-0054 (3.14 mg/kg)
Experimental
TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
干预措施: TG-0054 (3.14 mg/kg) (Drug)
结局指标
主要结局
Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD).
时间窗: 1 week
Patients who met the target CD34+ cell collection of ≧2 x 106 cells/kg after two apheresis sessions were classified as achieving mobilization success.
次要结局
- Fold Increase of Circulating CD34+ Cell Counts in Peripheral Blood.(Baseline, 3 hours and 6 hours after infusion)
- Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.(36 hrs after infusion)
- Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD.(36 hrs after infusion)
- Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.(36 hrs after infusion)
- The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD.(36 hrs after infusion)
- Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD.(36 hrs after infusion)
- Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.(36 hrs after infusion)
- Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.(36 hrs after infusion)
- The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD.(36 hrs after infusion)
- Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD.(36 hrs after infusion)
- Circulating CD34+ Cell Counts in Peripheral Blood.(Baseline, 3 hours and 6 hours after infusion)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin DiseaseNon-hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaNCT01458288GPCR Therapeutics, Inc.12
终止
2 期
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell DiseaseSickle Cell DiseaseNCT05445128Ensoma1
进行中（未招募）
2 期
Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype AFanconi Anemia Complementation Group ANCT04069533Rocket Pharmaceuticals Inc.7
进行中（未招募）
1 期
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler VariantMucopolysaccharidosis IHNCT03488394Orchard Therapeutics8
终止
2 期
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic MalignanciesRelated Donors Donating PBSC to a Family MemberHealthy DonorsAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeNCT04762875Ensoma7